['plaque psoriasis']
['fumaric acid esters', 'methotrexate', 'ixekizumab']

        Inclusion Criteria:

          -  Present with moderate-to-severe chronic plaque psoriasis based on a diagnosis of
             chronic psoriasis for at least 6 months before baseline.

          -  Participants who are candidates for systemic therapy and who are naive to systemic
             treatment for psoriasis.

          -  Have a (PASI score >10 or BSA >10) and DLQI >10 at screening and at baseline.

        Exclusion Criteria:

          -  Have predominant pattern of pustular, erythrodermic, and/or guttate forms of
             psoriasis.

          -  Have received systemic nonbiologic psoriasis therapy.

          -  Have prior, concurrent, or recent use of ixekizumab or any other biological psoriasis
             therapy.

          -  Have any condition or contraindication as addressed in the local labeling for MTX or
             FAE.

          -  Presence of significant uncontrolled cerebro-cardiovascular, respiratory, hepatic,
             renal, gastrointestinal, endocrine, hematologic, neurologic, or neuropsychiatric
             disorders or abnormal laboratory values at screening.

          -  Have severe gastrointestinal disease, oral ulcer, or known, active gastrointestinal
             ulcer.

          -  Have had a serious infection or are immunocompromised.

          -  At screening, participants with significant, present, or early liver disease, e.g.,
             explained by alcohol consumption or hepatic insufficiency.
      